• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of cancer immunotherapy based on understanding of intratumoral T-cell differentiation originating from stem-like CD8T cells

Research Project

Project/Area Number 21K07234
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 50020:Tumor diagnostics and therapeutics-related
Research InstitutionChiba University

Principal Investigator

Nasu Ryo  千葉大学, 大学院医学研究院, 講師 (30466859)

Co-Investigator(Kenkyū-buntansha) 岩立 康男  千葉大学, 大学院医学研究院, 教授 (70272309)
本橋 新一郎  千葉大学, 大学院医学研究院, 教授 (60345022)
Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2023: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2022: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2021: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywordsがん免疫 / CD69 / 腫瘍特異的CD8T細胞 / 所属リンパ節 / 幹細胞様CD8T細胞 / 分化型CD8T細胞 / 腫瘍内CD8T細胞分化 / 腫瘍内T細胞分化 / がん免疫療法 / 1細胞解析
Outline of Research at the Start

幹細胞様CD8T細胞は、PD-1/PD-L1免疫チェックポイント阻害剤の標的であることが明らかにされ、抗腫瘍免疫応答の要として重要視されている。本研究は主に、腫瘍内CD8T細胞の1細胞RNA-seq解析を行い、幹細胞様CD8T細胞の維持と分化のメカニズムを明らかにすることを目的としている。さらに、幹細胞様CD8T細胞の新規制御因子を探索し、腫瘍内T細胞分化の理解に基づく新規がん免疫療法の開発を目指す。

Outline of Final Research Achievements

In this study, we focused on the function of a newly identified target molecule, CD69, to elucidate the mechanisms of stem-like CD8T cell maintenance and differentiation. Single-cell RNA-seq analysis of tumor-specific CD8T cells suggested that CD69 deficiency promotes differentiation of stem-like CD8T cells into terminally differentiated CD8T cells in tumor-draining lymph nodes by suppressing the expression of the transcription factor TOX. Thus, CD69 is a novel therapeutic target that regulates CD8T cell differentiation in tumor-draining lymph nodes.

Academic Significance and Societal Importance of the Research Achievements

申請者らが新たに見出した標的分子であるCD69に着目した本研究は、国内外を通じて類似の研究がない独自で独創的な研究である。腫瘍所属リンパ節の腫瘍特異的CD8T細胞を治療標的とする免疫療法は、様々ながん種に対して有効な可能性があると考えている。今後、我々の知見からCD69を標的とした抗腫瘍効果の高いCD8T細胞分化を誘導する新規がん免疫療法が開発され、がん治療に新たな局面が拓かれることを期待している。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • Research Products

    (9 results)

All 2024 2023 2022 2021

All Journal Article (3 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 3 results,  Open Access: 2 results) Presentation (6 results) (of which Int'l Joint Research: 4 results,  Invited: 2 results)

  • [Journal Article] CD69 imposes tumor-specific CD8+ T cell fate in tumor-draining lymph nodes2023

    • Author(s)
      Koyama-Nasu Ryo、Kimura Motoko Y.、 Kiuchi Masahiro、 Aoki Ami、Wang Yangsong, Mita Yukiyoshi、Hasegawa Ichita、Endo Yukihiro、Onodera Atsushi、Hirahara Kiyoshi、 Motohashi Shinichiro、Nakayama Toshinori
    • Journal Title

      Cancer Immunology Research

      Volume: -

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] The cellular and molecular basis of CD69 function in anti-tumor immunity2022

    • Author(s)
      Koyama-Nasu Ryo、Wang Yangsong、Hasegawa Ichita、Endo Yukihiro、Nakayama Toshinori、Kimura Motoko Y
    • Journal Title

      International Immunology

      Volume: 34 Issue: 11 Pages: 555-561

    • DOI

      10.1093/intimm/dxac024

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] IFNγ suppresses the expression of GFI1 and thereby inhibits Th2 cell proliferation2021

    • Author(s)
      Sarkar Murshed H.、Yagi Ryoji、Endo Yukihiro、Koyama-Nasu Ryo、Wang Yangsong、Hasegawa Ichita、Ito Toshihiro、Junttila Ilkka S.、Zhu Jinfang、Kimura Motoko Y.、Nakayama Toshinori
    • Journal Title

      PLOS ONE

      Volume: 16 Issue: 11 Pages: e0260204-e0260204

    • DOI

      10.1371/journal.pone.0260204

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] CD69 regulates tumor-specific CD8 T cell differentiation in tumor-draining lymph nodes2024

    • Author(s)
      Ryo Nasu, Yangsong Wang, Yukihiro Endo, Ichita Hasegawa, Yukiyoshi Mita, Shinichiro Motohashi, Toshinori Nakayama, Motoko Y. Kimura
    • Organizer
      第52回 日本免疫学会学術集会
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] CD69 controls differentiation of tumor-specific CD8T cells in tumor-draining lymph nodes2023

    • Author(s)
      Ryo Nasu, Yangsong Wang, Yukihiro Endo, Ichita Hasegawa, Yukiyoshi Mita, Shinichiro Motohashi, Toshinori Nakayama, Motoko Y. Kimura
    • Organizer
      第82回日本癌学会学術総会
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] CD69 regulates anti-tumor CD8T cell responses2022

    • Author(s)
      Ryo Nasu, Yangsong Wang, Yukihiro Endo, Ichita Hasegawa, Atsushi Onodera, Shinichiro Motohashi, Toshinori Nakayama, Motoko Y. Kimura
    • Organizer
      第51回日本免疫学会学術集会
    • Related Report
      2022 Research-status Report
    • Int'l Joint Research
  • [Presentation] 腫瘍特異的CD8T細胞の分化運命決定機構2022

    • Author(s)
      那須 亮, Wang Yangsong, 長谷川 一太, 遠藤 将大, 中山 俊憲, 木村 元子.
    • Organizer
      KTCC第31回学術集会
    • Related Report
      2022 Research-status Report
  • [Presentation] CD69 regulates anti-tumor immunity2021

    • Author(s)
      Kimura M., Nasu R., Mita Y., Wang Y., Endo Y., Hasegawa I., Motohashi S., Nakayama T.
    • Organizer
      The 50th Annual Meeting of the Japanese Society for Immunology
    • Related Report
      2021 Research-status Report
    • Int'l Joint Research / Invited
  • [Presentation] CD69-Myl9システムと炎症制御2021

    • Author(s)
      木村元子, 横山将也, 小林弘信, 林﨑浩史, 遠藤将大, Wang Yangsong, 長谷川一太, 那須亮, 中山俊憲
    • Organizer
      第44回日本分子生物学会年会
    • Related Report
      2021 Research-status Report
    • Invited

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi